ID

22392

Descripción

Study to Evaluate Initiation of Stalevo in Early Wearing-off; ODM derived from: https://clinicaltrials.gov/show/NCT00462007

Link

https://clinicaltrials.gov/show/NCT00462007

Palabras clave

Versiones (1)
  1. 1/6/17 1/6/17 -
Subido en

1 de junio de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Parkinson's Disease NCT00462007

Inglés

Eligibility Parkinson's Disease NCT00462007

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects with idiopathic parkinson's disease and early wearing-off symptoms treated with standard levodopa/ddci treatment
Descripción

Parkinson Disease | Levodopa | DOPA Decarboxylase Inhibitors | Wearing off effect Early

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0030567
UMLS CUI [2]
C0023570
UMLS CUI [3]
C0598272
UMLS CUI [4,1]
C1504539
UMLS CUI [4,2]
C1279919
age >35 - years
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
hoehn and yahr stage 1-3 performed during the 'on'-stage
Descripción

Hoehn and Yahr Stage | Pharmaceutical Preparations Use of

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3639483
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1524063
at least 1 symptom identified by woq-9
Descripción

Symptoms Quantity Identified Wearing off Questionnaire

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0205396
UMLS CUI [1,4]
C1504539
UMLS CUI [1,5]
C0034394
dosing frequency of 3-4 doses of standard-release levodopa/ddci (maximum total daily dose of 600 mg of levodopa)
Descripción

Levodopa Dose U/day Maximum | DOPA Decarboxylase Inhibitors Dose Frequency

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0023570
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0456683
UMLS CUI [1,4]
C0806909
UMLS CUI [2,1]
C0598272
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0439603
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
atypical or symptomatic parkinson's disease
Descripción

Atypical Parkinson Disease | Secondary Parkinson Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1868596
UMLS CUI [2]
C0030569
unpredictable off-periods
Descripción

UPDRS - Off Periods Unpredictable

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3639872
any peak-dose dyskinesia. 'off'-state dystonia is allowed
Descripción

Dyskinetic syndrome Peak Dose | Dystonia Pharmaceutical Preparations Off

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013384
UMLS CUI [1,2]
C0444505
UMLS CUI [1,3]
C0178602
UMLS CUI [2,1]
C0013421
UMLS CUI [2,2]
C0013227
UMLS CUI [2,3]
C1518543
use of any rescue medications to treat symptoms of 'off'-state. 1 dose of soluble levodopa/ddci is allowed.
Descripción

Pharmaceutical Preparations Additional | Levodopa Dose Quantity | DOPA Decarboxylase Inhibitors Dose Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1524062
UMLS CUI [2,1]
C0023570
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C1265611
UMLS CUI [3,1]
C0598272
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C1265611
concomitant treatment with non-selective monoamine oxidase (mao) inhibitor or simultaneous use of higher than recommended doses of mao-a and mao-b inhibitors (selegiline 10 mg or rasagiline 1 mg allowed) or use of apomorphine.
Descripción

Monoamine oxidase inhibitors, non-selective | Monoamine Oxidase-A Inhibitors High dose | Monoamine Oxidase-B Inhibitors High dose | Selegiline Dose | Rasagiline Dose | Apomorphine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3653330
UMLS CUI [2,1]
C2917289
UMLS CUI [2,2]
C0444956
UMLS CUI [3,1]
C2917290
UMLS CUI [3,2]
C0444956
UMLS CUI [4,1]
C0036579
UMLS CUI [4,2]
C0178602
UMLS CUI [5,1]
C0525678
UMLS CUI [5,2]
C0178602
UMLS CUI [6]
C0003596
Volver a la parte superior de la página

Similar models

Eligibility Parkinson's Disease NCT00462007

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Parkinson Disease | Levodopa | DOPA Decarboxylase Inhibitors | Wearing off effect Early
Item
subjects with idiopathic parkinson's disease and early wearing-off symptoms treated with standard levodopa/ddci treatment
boolean
C0030567 (UMLS CUI [1])
C0023570 (UMLS CUI [2])
C0598272 (UMLS CUI [3])
C1504539 (UMLS CUI [4,1])
C1279919 (UMLS CUI [4,2])
Age
Item
age >35 - years
boolean
C0001779 (UMLS CUI [1])
Hoehn and Yahr Stage | Pharmaceutical Preparations Use of
Item
hoehn and yahr stage 1-3 performed during the 'on'-stage
boolean
C3639483 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
Symptoms Quantity Identified Wearing off Questionnaire
Item
at least 1 symptom identified by woq-9
boolean
C1457887 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0205396 (UMLS CUI [1,3])
C1504539 (UMLS CUI [1,4])
C0034394 (UMLS CUI [1,5])
Levodopa Dose U/day Maximum | DOPA Decarboxylase Inhibitors Dose Frequency
Item
dosing frequency of 3-4 doses of standard-release levodopa/ddci (maximum total daily dose of 600 mg of levodopa)
boolean
C0023570 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
C0806909 (UMLS CUI [1,4])
C0598272 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0439603 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Atypical Parkinson Disease | Secondary Parkinson Disease
Item
atypical or symptomatic parkinson's disease
boolean
C1868596 (UMLS CUI [1])
C0030569 (UMLS CUI [2])
UPDRS - Off Periods Unpredictable
Item
unpredictable off-periods
boolean
C3639872 (UMLS CUI [1])
Dyskinetic syndrome Peak Dose | Dystonia Pharmaceutical Preparations Off
Item
any peak-dose dyskinesia. 'off'-state dystonia is allowed
boolean
C0013384 (UMLS CUI [1,1])
C0444505 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0013421 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C1518543 (UMLS CUI [2,3])
Pharmaceutical Preparations Additional | Levodopa Dose Quantity | DOPA Decarboxylase Inhibitors Dose Quantity
Item
use of any rescue medications to treat symptoms of 'off'-state. 1 dose of soluble levodopa/ddci is allowed.
boolean
C0013227 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0023570 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0598272 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Monoamine oxidase inhibitors, non-selective | Monoamine Oxidase-A Inhibitors High dose | Monoamine Oxidase-B Inhibitors High dose | Selegiline Dose | Rasagiline Dose | Apomorphine
Item
concomitant treatment with non-selective monoamine oxidase (mao) inhibitor or simultaneous use of higher than recommended doses of mao-a and mao-b inhibitors (selegiline 10 mg or rasagiline 1 mg allowed) or use of apomorphine.
boolean
C3653330 (UMLS CUI [1])
C2917289 (UMLS CUI [2,1])
C0444956 (UMLS CUI [2,2])
C2917290 (UMLS CUI [3,1])
C0444956 (UMLS CUI [3,2])
C0036579 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0525678 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0003596 (UMLS CUI [6])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial